EA201892184A1 - Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора - Google Patents

Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора

Info

Publication number
EA201892184A1
EA201892184A1 EA201892184A EA201892184A EA201892184A1 EA 201892184 A1 EA201892184 A1 EA 201892184A1 EA 201892184 A EA201892184 A EA 201892184A EA 201892184 A EA201892184 A EA 201892184A EA 201892184 A1 EA201892184 A1 EA 201892184A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monoclonal antibodies
tissue factor
antibodies
tfpi
antibodies against
Prior art date
Application number
EA201892184A
Other languages
English (en)
Russian (ru)
Inventor
Петер Шольц
Зуози Ванг
Юнлианг Пан
Ёанна Грудзинска
Кристиан Фотсмайер
Ян Теббе
Йорг Биркенфельд
Нина Вобст
Зимоне Брюкнер
Зузанне Штайниг
Original Assignee
БАЙЕР ХЕЛЬСКЕР ЛЛСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44542552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201892184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by БАЙЕР ХЕЛЬСКЕР ЛЛСи filed Critical БАЙЕР ХЕЛЬСКЕР ЛЛСи
Publication of EA201892184A1 publication Critical patent/EA201892184A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Filtering Materials (AREA)
EA201892184A 2010-03-01 2011-03-01 Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора EA201892184A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30929010P 2010-03-01 2010-03-01

Publications (1)

Publication Number Publication Date
EA201892184A1 true EA201892184A1 (ru) 2019-03-29

Family

ID=44542552

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201290849A EA032189B9 (ru) 2010-03-01 2011-03-01 Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
EA201892184A EA201892184A1 (ru) 2010-03-01 2011-03-01 Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201290849A EA032189B9 (ru) 2010-03-01 2011-03-01 Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их

Country Status (37)

Country Link
US (3) USRE47150E1 (enExample)
EP (2) EP2542257B1 (enExample)
JP (4) JP6025570B2 (enExample)
KR (4) KR20190047135A (enExample)
CN (5) CN102939098B (enExample)
AU (1) AU2011223710B2 (enExample)
BR (1) BR112012022258A2 (enExample)
CA (3) CA2976671C (enExample)
CL (2) CL2012002415A1 (enExample)
CO (1) CO6620068A2 (enExample)
CR (1) CR20120453A (enExample)
CU (1) CU23982B1 (enExample)
CY (2) CY1119410T1 (enExample)
DK (2) DK3345615T3 (enExample)
DO (1) DOP2012000239A (enExample)
EA (2) EA032189B9 (enExample)
EC (2) ECSP12012134A (enExample)
ES (2) ES2642512T3 (enExample)
GT (1) GT201200252A (enExample)
HK (2) HK1232232A1 (enExample)
HR (2) HRP20171472T1 (enExample)
HU (2) HUE036655T2 (enExample)
IL (3) IL221551B (enExample)
LT (2) LT2542257T (enExample)
ME (2) ME03578B (enExample)
MX (2) MX2012010198A (enExample)
MY (1) MY174760A (enExample)
NZ (2) NZ602115A (enExample)
PE (1) PE20160538A1 (enExample)
PH (4) PH12012501742A1 (enExample)
PL (2) PL3345615T3 (enExample)
PT (2) PT3345615T (enExample)
RS (2) RS59830B1 (enExample)
SG (3) SG10201502587SA (enExample)
SI (2) SI2542257T1 (enExample)
SM (1) SMT201700454T1 (enExample)
WO (1) WO2011109452A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CA2745317C (en) † 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
AU2011223710B2 (en) 2010-03-01 2016-04-14 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2588499B1 (en) * 2010-06-30 2020-04-08 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
EP2694544B1 (en) * 2011-04-01 2019-01-23 Bayer HealthCare LLC Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US9975962B2 (en) * 2012-03-30 2018-05-22 Bayer Healthcare Llc Thrombin/plasmin-regulated antibodies that bind TFPI
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN105209496A (zh) * 2013-03-15 2015-12-30 拜尔健康护理有限责任公司 针对组织因子途径抑制剂的前体药物抗体
HRP20180078T1 (hr) * 2013-03-15 2018-03-09 Bayer Healthcare Llc VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE
EP4279128A3 (en) * 2015-02-25 2024-02-28 Mogam Institute for Biomedical Research Novel antibody binding to tfpi and composition comprising the same
JP6664467B2 (ja) * 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
US20210395391A1 (en) * 2018-10-11 2021-12-23 Pfizer Inc. Dosage Regimen for TFPI Antagonists
KR102692277B1 (ko) * 2019-03-11 2024-08-05 현대자동차주식회사 상용 전기차용 모터 마운트
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
EP0465513A1 (en) 1989-03-27 1992-01-15 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DE4223132A1 (de) 1992-07-14 1994-01-20 Deutsche Aerospace Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
WO1994019020A1 (en) 1993-02-23 1994-09-01 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0876140B1 (de) 1996-01-25 2003-10-15 Schering Aktiengesellschaft Verbesserte kontrastmittenlösungen für die intravasale anwendung
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US20040052799A1 (en) 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
EP1000161B1 (en) 1997-03-26 2006-02-22 Imperial College Innovations Limited Anticoagulant fusion protein anchored to cell membrane
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
DE59806877D1 (de) 1997-08-21 2003-02-13 Siemens Ag Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU3006799A (en) 1998-03-12 1999-09-27 Human Genome Sciences, Inc. 31 human secreted proteins
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20020160934A1 (en) 2000-01-14 2002-10-31 Julie Broadus Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
EP1260230A4 (en) 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
EP1272211B1 (en) 2000-04-07 2007-06-06 Signal Coordinating Therapy, Inc. Methods and compositions for treating neoplasms
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
EP1930024A3 (en) 2000-09-01 2008-08-06 Chugai Seiyaku Kabushiki Kaisha G-CSF solution formulations having long-term stability
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
CA2434323A1 (en) 2001-02-07 2002-11-28 Centre National De La Recherche Scientifique (Cnrs) Sequence of the photorhabdus luminescens strain tt01 genome and uses
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6891085B2 (en) 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
CA2387401C (en) 2001-05-21 2004-10-12 Ecopia Biosciences Inc. Compositions, methods and systems for the production of enediynes
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
KR20050036852A (ko) 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-ｈｌａ-ｄｒ 항체
EP1441748A4 (en) 2001-10-16 2007-07-11 Rxkinetix Inc HIGHLY CONCENTRATED PROTEIN FORMULATIONS AND MANUFACTURING METHOD
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20030166004A1 (en) 2001-11-01 2003-09-04 Jeno Gyuris Endothelial-cell binding peptides for diagnosis and therapy
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
US20050203280A1 (en) 2001-11-29 2005-09-15 Mcmichael John C. Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2003062375A2 (en) 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
US20030157082A1 (en) 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
DE60334678D1 (de) 2002-02-14 2010-12-09 Chugai Pharmaceutical Co Ltd Antikörper enthaltende pharmazeutische lösungen
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP1478394B1 (en) 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
WO2003076575A2 (en) 2002-03-04 2003-09-18 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2492143A1 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
ES2357948T3 (es) 2002-10-08 2011-05-04 Rinat Neuroscience Corp. Procedimientos para tratar dolor postquirúrgico mediante la administración de un anticuerpo frente al factor de crecimiento nervioso y composiciones que contienen el mismo.
KR100542401B1 (ko) 2002-10-23 2006-01-11 한국전자통신연구원 인터넷 차별 서비스 망에서의 연결 수락 제어방법
EP1578947A4 (en) 2002-12-02 2006-12-06 Abgenix Inc ANTIBODIES TAKEN AGAINST PHOSPHOLIPASE A2 AND USES THEREOF
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
CA2511598C (en) 2002-12-24 2016-09-13 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
MX295545B (es) 2003-03-07 2012-02-03 Diversa Corp Hidrolasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas.
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
TWI503328B (zh) 2003-07-15 2015-10-11 Amgen Inc 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
AR042955A1 (es) 2003-07-18 2005-07-13 Amgen Inc Agentes de union especifica al factor de crecimiento de hepatocitos
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
DE602004026474D1 (de) 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
EP2287178A3 (en) 2004-01-09 2011-05-18 Novozymes, Inc. Bacillus licheniformis YvmC inactivation
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
CN102139106B (zh) 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
CA2564791A1 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
US20080267971A1 (en) 2004-12-21 2008-10-30 Green Larry L Antibodies Directed to Angiopoietin-2 and Uses Thereof
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
ES2381203T3 (es) 2005-01-27 2012-05-24 Novimmune Sa Anticuerpos anti-interferón gamma humanos y métodos de uso de los mismos
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2006092449A2 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US7682808B2 (en) 2005-03-04 2010-03-23 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
WO2006096489A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
KR101280273B1 (ko) 2005-04-18 2013-07-15 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정화된 항-ｂ형 간염 바이러스 (ｈｂｖ) 항체 제형
US7889636B2 (en) 2005-05-24 2011-02-15 Cisco Technology, Inc. System and method for implementing a mid-call policy in a RSVP environment
GB2426887B (en) 2005-06-04 2009-01-07 Ibm Client responsibilities in messaging systems
US20090148406A1 (en) 2005-07-02 2009-06-11 Arecor Limited Stable Aqueous Systems Comprising Proteins
EA014513B1 (ru) 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
US20070086433A1 (en) 2005-10-19 2007-04-19 Cunetto Philip C Methods and apparatus for allocating shared communication resources to outdial communication services
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
RU2470941C2 (ru) 2005-12-02 2012-12-27 Дженентек, Инк. Связывающие полипептиды и их применения
US7669228B2 (en) 2005-12-27 2010-02-23 Cisco Technology, Inc. System and method for changing network behavior based on presence information
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
WO2007112054A2 (en) 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
US8355333B2 (en) 2006-08-31 2013-01-15 Ciena Corporation Methods and systems for session initiation protocol control of network equipment
WO2008045563A2 (en) 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
AU2007331712A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
LT2170390T (lt) 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
ES2566963T3 (es) * 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
AU2008340429C1 (en) 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
EP2240156A2 (en) 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
ES2562627T3 (es) 2008-02-20 2016-03-07 Novo Nordisk A/S Anticuerpos anti-C5aR humanizados
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
CA2728685A1 (en) 2008-06-30 2010-01-07 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US10188600B2 (en) 2008-09-19 2019-01-29 Pfizer Inc. Stable liquid antibody formulation
EP2350649A4 (en) 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
BRPI0922344A2 (pt) 2008-12-19 2017-10-24 3B Pharmaceuticals Gmbh inibidores de tfpi e métodos de uso
JP5791512B2 (ja) 2008-12-22 2015-10-07 ノヴォ ノルディスク アー／エス 組織因子経路阻害因子（ｔｆｐｉ）に対する抗体
CA2745317C (en) 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
KR20120027031A (ko) 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
EP2805731B1 (en) 2009-09-03 2018-10-31 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
AU2011223710B2 (en) 2010-03-01 2016-04-14 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
EP2673364A1 (en) 2011-02-11 2013-12-18 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
EP2694544B1 (en) 2011-04-01 2019-01-23 Bayer HealthCare LLC Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AU2013235567A1 (en) 2012-03-22 2014-10-09 Baxalta GmbH Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
HRP20180078T1 (hr) 2013-03-15 2018-03-09 Bayer Healthcare Llc VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE
EP4279128A3 (en) 2015-02-25 2024-02-28 Mogam Institute for Biomedical Research Novel antibody binding to tfpi and composition comprising the same
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用

Also Published As

Publication number Publication date
HRP20171472T1 (hr) 2017-12-01
MX354743B (es) 2018-03-16
LT3345615T (lt) 2020-02-10
IL262444B (en) 2021-01-31
LT2542257T (lt) 2017-11-27
CN110835373A (zh) 2020-02-25
PL3345615T3 (pl) 2020-07-13
PE20160538A1 (es) 2016-05-19
RS59830B1 (sr) 2020-02-28
SG10201903166PA (en) 2019-05-30
SI3345615T1 (sl) 2020-03-31
CL2012002415A1 (es) 2013-08-23
ME03578B (me) 2020-07-20
NZ602115A (en) 2014-12-24
PH12018500639A1 (en) 2019-07-29
CA2791685A1 (en) 2011-09-09
RS56409B1 (sr) 2018-01-31
KR101807894B1 (ko) 2017-12-12
HK1254947A1 (zh) 2019-08-02
JP6025570B2 (ja) 2016-11-16
ES2642512T3 (es) 2017-11-16
IL262444A (en) 2018-12-31
PL2542257T3 (pl) 2018-01-31
DK3345615T3 (da) 2020-01-20
US9309324B2 (en) 2016-04-12
KR20180091116A (ko) 2018-08-14
US8481030B2 (en) 2013-07-09
CN102939098B (zh) 2016-08-03
SMT201700454T1 (it) 2018-01-11
US20120108796A1 (en) 2012-05-03
PT3345615T (pt) 2020-01-17
CL2017003218A1 (es) 2018-06-08
EP2542257A4 (en) 2013-11-13
PH12018500641A1 (en) 2019-07-29
NZ702494A (en) 2016-09-30
JP6684369B2 (ja) 2020-04-22
EP2542257B1 (en) 2017-07-05
CA2791685C (en) 2019-07-23
CA3101298A1 (en) 2011-09-09
SI2542257T1 (en) 2018-01-31
AU2011223710B2 (en) 2016-04-14
IL277391A (en) 2020-11-30
PT2542257T (pt) 2017-10-09
JP2013520996A (ja) 2013-06-10
CU23982B1 (es) 2014-03-26
CN106188301A (zh) 2016-12-07
USRE47150E1 (en) 2018-12-04
GT201200252A (es) 2014-04-03
CN107987166A (zh) 2018-05-04
SG10201502587SA (en) 2015-06-29
ECSP19025350A (es) 2019-04-30
ME02894B (me) 2018-04-20
KR101974980B1 (ko) 2019-05-07
CY1122476T1 (el) 2021-01-27
CY1119410T1 (el) 2018-03-07
ECSP12012134A (es) 2012-09-28
KR101903931B1 (ko) 2018-10-02
MY174760A (en) 2020-05-13
EA032189B9 (ru) 2019-09-30
ES2765418T3 (es) 2020-06-09
PH12012501742A1 (en) 2022-03-21
CN105001335B (zh) 2019-10-25
DK2542257T3 (en) 2017-10-16
EP3345615B1 (en) 2019-10-16
IL221551B (en) 2019-08-29
EA032189B1 (ru) 2019-04-30
MX2012010198A (es) 2012-10-03
PH12018500640A1 (en) 2019-07-29
JP2019089807A (ja) 2019-06-13
CR20120453A (es) 2013-02-27
EA201290849A1 (ru) 2013-05-30
CN105001335A (zh) 2015-10-28
CA2976671A1 (en) 2011-09-09
CN102939098A (zh) 2013-02-20
KR20190047135A (ko) 2019-05-07
JP2017035100A (ja) 2017-02-16
HRP20192295T1 (hr) 2020-03-20
HUE047173T2 (hu) 2020-04-28
US20120329996A1 (en) 2012-12-27
BR112012022258A2 (pt) 2016-10-25
WO2011109452A1 (en) 2011-09-09
AU2011223710A1 (en) 2012-09-20
KR20130004586A (ko) 2013-01-11
CA2976671C (en) 2021-01-12
SG183443A1 (en) 2012-09-27
CO6620068A2 (es) 2013-02-15
HK1232232A1 (zh) 2018-01-05
EP2542257A1 (en) 2013-01-09
EP3345615A1 (en) 2018-07-11
CU20120126A7 (es) 2013-01-30
DOP2012000239A (es) 2013-08-15
KR20170137218A (ko) 2017-12-12
JP6475679B2 (ja) 2019-02-27
JP2020115868A (ja) 2020-08-06
HUE036655T2 (hu) 2018-07-30

Similar Documents

Publication Publication Date Title
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
EA201100923A1 (ru) Антитела человека против тканевого фактора
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
IN2014CN03936A (enExample)
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
EA201590918A1 (ru) Антитела к bmp-6
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
EA201390117A1 (ru) Композиция антител к vegfr-3
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
EA202190387A1 (ru) Антитело к cd38 человека и его применение